Health,
Obstetrics,
Faculty,
Gynaecology,
Physician,
FACOG,
DEL,
Memorial Hermann–Texas Medical Center,
Lung,
Breast,
University,
MD,
Biology,
Ovary,
Cancer,
Liquid biopsy,
GeneDx,
Occidental College DEL MAR, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Genece Health, a molecular testing company focused on improving cancer detection for lung, breast, ovarian and other cancers, today announced that Marra Francis, MD, FACOG, has joined the company as its chief medical officer.
Key Points:
- DEL MAR, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Genece Health, a molecular testing company focused on improving cancer detection for lung, breast, ovarian and other cancers, today announced that Marra Francis, MD, FACOG, has joined the company as its chief medical officer.
- Dr. Francis’ past experience also includes serving as head of medical affairs for women's health of Sema4 (now GeneDx); as executive medical director of EverlyWell; and as chief medical officer of Aspira Women's Health.
- Dr. Francis holds a medical degree from the University of Connecticut Health Center and a bachelor of arts degree in biology from Occidental College.
- “We are delighted to have Marra join our team at a very exciting time for Genece,” said Greg Gosch, CEO of Genece Heath.
Retrieved on:
Wednesday, March 20, 2024
DEL MAR, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Genece Health, a molecular testing company focused on improving cancer screening for lung, breast, ovarian and other cancers, today announced that four abstracts demonstrating their deep-learning AI and liquid biopsy technology’s performance were selected for presentation at the upcoming 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA.
Key Points:
- DEL MAR, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Genece Health, a molecular testing company focused on improving cancer screening for lung, breast, ovarian and other cancers, today announced that four abstracts demonstrating their deep-learning AI and liquid biopsy technology’s performance were selected for presentation at the upcoming 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA.
- This will be the first time performance data from the company will be shared publicly.
- The abstracts will be available on the AACR website and poster presentation details can be found below.
- Session Title: Advances in Genomic Sequencing Platforms, Methodologies, and Interpretation 1
